Tuberkulózis: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• TNF 0
• IL-1 0
• IL-6 0
• IL-17 0
• STING 0
• NLRP3 0
• STAT3 0
• HMGB1 0
• JAK 0
• PD-1 0
• PI3K 0
• TLR4 0
• TP53 0
• TYK2 0
• AKT 0
• CTLA-4 0
• IL-23 0
• mTOR 0
• NRF2 0
• PPAR 0
• SIRT1 0
• CCR5 0
• CD40 0
• EGFR 0
• MAPK 0
• PD-L1 0
• ABL1 0
• AMPK 0
• CD20 0
• COX-2 0
• GPX4 0
• JNK 0
• TFEB 0
• TREM2 0
• VEGF 0
• YAP 0
• ALK 0
• ATM 0
• AXL 0
• BCL-2 0
• BRAF 0
• CD38 0
• FTO 0
• HDAC 0
• HIF-1 0
• HSP90 0
• IL-15 0
• IL-4 0
• MMP-9 0
• NOTCH3 0
• NTRK 0
• PDE4 0
• PKM2 0
• PRMT5 0
• PTEN 0
• STK11 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Human JAK2 genotypes underlying tuberculosis (JAK2-TB)

  Imagine Institut des Maladies Genetiques Necker Enfants Malades Fondation· Paris, Franciaország· EU contribution 242 261 EUR· until 2029. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-Cofund-CE

  Empowering the Next Generation of Researchers for Advancing Global Antimicrobial Resistance Endeavors (ENGAGE)

  Valsts zinatniskais instituts ""Nacionalais petniecibas un inovaciju instituts""""· Riga, Lettország· EU contribution 1 206 000 EUR· until 2031. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research (PATHFINDER)

  Imperial College of Science Technology and Medicine· London, Egyesült Királyság· EU contribution 2 753 896 EUR· until 2030. márc.· 4 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Deciphering the molecular architecture and infection mechanisms of corynephages within native host environments (ISPHAGE)

  Universite de Lausanne· Lausanne, Svájc· EU contribution 292 119 EUR· until 2028. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  An equity microsimulation approach to forecast the impact of social protection on diseases of poverty in low- and middle-income countries: the case of tuberculosis (SIMPACT-TB)

  Fundacion Privada Instituto de Salud Global Barcelona· Barcelona, Spanyolország· EU contribution 209 915 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-RIA

  COMMUNITY-BASED SCALE UP OF INTEGRATED COMMUNITY HEALTH WORKER-LED CARDIOVASCULAR RISK FACTOR MANAGEMENT - ComBaScale

  Instituut Voor Tropische Geneeskunde· Antwerpen, Belgium· EU contribution 3 999 621 EUR· until 2031. aug.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  A Phase 2a Randomised Clinical Trial to Identify the Optimal Dose of the Thermostable ID93+GLA-SE Tuberculosis Vaccine for Further Clinical Evaluation and Local Manufacture in Africa (ACTTIVAC)

  Stichting Tuberculosis Vaccine Initiative· Lelystad, Hollandia· EU contribution 11 943 469 EUR· until 2030. júl.· 4 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children (ACT4KIDS-TB)

  Instituut Voor Tropische Geneeskunde· Antwerpen, Belgium· EU contribution 2 059 164 EUR· until 2030. júl.· 4 countries

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Hollandia· EU contribution 12 751 885 EUR· until 2031. jún.· 14 countries

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  Training Initiative for Modeling Epidemic Response in Africa (TIMERA)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Hollandia· EU contribution 1 299 010 EUR· until 2029. jún.· 4 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 62 running projects, newest first. Listed amounts together: 453,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 33
• Organoids 5
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 25
• Gene Expression Profiling 103
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 136
• Exome Sequencing 5
• Proteomics 47
• Metabolomics 39
• Mass Spectrometry 16
• Flow Cytometry 16
• Immunohistochemistry 9
• Positron-Emission Tomography 3
• Magnetic Resonance Imaging 85
• Machine Learning 102
• Deep Learning 41
• Cohort Studies 103
• Genome-Wide Association Study 12

• Delayed diagnosis of cystic fibrosis: clinical burden and missed opportunities in a cohort from Rio de Janeiro, Brazil.

  Respir Res Clin Pract, 2026. szept.

• Diagnosis-time risk stratification for tuberculosis mortality in a nationwide public-private mix program.

  Int J Infect Dis, 2026. szept.

• High levels of recurrent TB in the Philippines: results from a rural community cohort using a pragmatic design.

  Int J Tuberc Lung Dis, 2026. aug.

• Frequency and prognostic outcomes of emergency diagnosis in 13 non-neoplastic conditions in England: A population-based cohort study using linked electronic health records of 1.7 million patients.

  PLoS Med, 2026. aug.

• PPD skin test positivity and in-hospital mortality across age groups in non-HIV tuberculous meningitis: a retrospective cohort study.

  Front Neurol, 2026. aug.

• Temporal trends and age-period-cohort effects of tuberculosis incidence among older adults in western China, 2005-2020.

  BMC Geriatr, 2026. aug.

• Trends and treatment outcomes of TB among people living with HIV: a nationwide cohort study, 2011-2022.

  Int J Tuberc Lung Dis, 2026. júl.

• Risk factors for tuberculosis: a nationwide cohort study among Greenlanders in Denmark, 2005-2022, highlighting social vulnerability.

  BMC Public Health, 2026. júl.

• Paradoxical reactions in pediatric HIV-negative CNS tuberculosis: A longitudinal cohort study.

  Eur J Paediatr Neurol, 2026. júl.

• Tuberculosis screening in adult patients with inborn errors of immunity: a single-center cohort study.

  Front Immunol, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.